Archive for the 'Respiratory Tract' Category

30 Nov

Sequential Intravenous-Oral Administration of Ciprofloxacin vs Ceftazidime in Serious Bacterial Respiratory Tract Infections: Cost Analysis

Cost Analysis Intravenous ciprofloxacin or another comparable intravenous quinolone has, as yet, not been approved by federal drug agency, and thus, the market cost of the intravenous preparation is not available. However, comparable cost analysis of oral ciprofloxacin with other conventional therapies is available. In one study, IV cefotaxime was compared with oral ciprofloxacin in […]

29 Nov

Sequential Intravenous-Oral Administration of Ciprofloxacin vs Ceftazidime in Serious Bacterial Respiratory Tract Infections: Penetration of the drug

The average penetration of the drug into bronchial mucosa was 161 percent but was found to be quite variable. Although the sputum levels are low, the bronchial mucosa levels are very high. Marlin et al studied the distribution ratio of enoxacin between plasma and bronchial mucosa in patients after distribution equilibrium was established. They also […]

28 Nov

Sequential Intravenous-Oral Administration of Ciprofloxacin vs Ceftazidime in Serious Bacterial Respiratory Tract Infections: Bronchial mucosa

The four quinolones, enoxacin, pefloxacin, ciprofloxacin, ofloxacin, have unique properties of penetrating into the bronchial lining and achieving high concentrations in the lung, in the bronchial mucosa, and in the sputum. Bergogne et al studied 21 patients who received a single oral dose of 500 mg ciprofloxacin. Ten successive samples of the sputum were collected […]

27 Nov

Sequential Intravenous-Oral Administration of Ciprofloxacin vs Ceftazidime in Serious Bacterial Respiratory Tract Infections: Role of ciprofloxacin

In our center, the most common bacteria identified during exacerbations of chronic lung disease or nosocomial infection are Hemophilus, Pseudomonas aeruginosa, Klebsiella, and Staphylococcus aureus. These organisms, as well as other Gram-negative and Gram-positive organisms tested, were highly susceptible to ciprofloxacin with MICs of 1 jig/ml or less in all cases. Thus, ciprofloxacin can be […]

26 Nov

Sequential Intravenous-Oral Administration of Ciprofloxacin vs Ceftazidime in Serious Bacterial Respiratory Tract Infections: Cystic Fibrosis

Cystic Fibrosis A number of studies have reported on the effectiveness of oral ciprofloxacin in the treatment of bacterial infection in cystic fibrosis. Oral ciprofloxacin is of special interest in the treatment of patients with cystic fibrosis in view of ciprofloxacins special activity against Pseudomonas aeruginosa, S aureus, and Hemophilus influenzae, the three pathogens which, […]

25 Nov

Sequential Intravenous-Oral Administration of Ciprofloxacin vs Ceftazidime in Serious Bacterial Respiratory Tract Infections: Discussion

Oral ciprofloxacin has been found to be quite effective in the treatment of various forms of respiratory tract infection. Contrary to the favorable results found by Gleedhill et al and Kobayashi, Davies, in his study of oral ciprofloxacin for respiratory tract infection, reported several problems; most of the problems were due to resistance or recurrence […]

24 Nov

Sequential Intravenous-Oral Administration of Ciprofloxacin vs Ceftazidime in Serious Bacterial Respiratory Tract Infections: Microbiologic Results

Microbiologic Results Table 1 summarizes the type and number of isolates recovered in the 87 patients, as well as the disk susceptibility for these isolates and the available MIC values of 118 isolates. Significantly more isolates were susceptible to ciprofloxacin than to ceftazidime as determined by the diflusion technique. The MIC values reveal that ciprofloxacin […]

Pages: 1 2 Next

© 2008 HIV/AIDS News & Information